TW200503683A - Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain - Google Patents

Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain

Info

Publication number
TW200503683A
TW200503683A TW092129615A TW92129615A TW200503683A TW 200503683 A TW200503683 A TW 200503683A TW 092129615 A TW092129615 A TW 092129615A TW 92129615 A TW92129615 A TW 92129615A TW 200503683 A TW200503683 A TW 200503683A
Authority
TW
Taiwan
Prior art keywords
methods
pain
compositions
management
modification
Prior art date
Application number
TW092129615A
Other languages
Chinese (zh)
Inventor
Jerome B Zeldis
Herbert Faleck
Donald C Manning
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of TW200503683A publication Critical patent/TW200503683A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychological or physical therapy. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
TW092129615A 2002-10-24 2003-10-24 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain TW200503683A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42100302P 2002-10-24 2002-10-24

Publications (1)

Publication Number Publication Date
TW200503683A true TW200503683A (en) 2005-02-01

Family

ID=32176661

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092129615A TW200503683A (en) 2002-10-24 2003-10-24 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain

Country Status (13)

Country Link
EP (1) EP1556044A2 (en)
JP (1) JP2006507284A (en)
KR (1) KR20050057672A (en)
CN (2) CN101108185A (en)
AU (1) AU2003286663B2 (en)
BR (1) BR0315609A (en)
CA (1) CA2503536A1 (en)
HK (1) HK1088225A1 (en)
MX (1) MXPA05004182A (en)
NZ (1) NZ540028A (en)
TW (1) TW200503683A (en)
WO (1) WO2004037199A2 (en)
ZA (1) ZA200503240B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US20080300262A1 (en) * 2005-04-08 2008-12-04 Snutch Terrance P Combination Therapy for Relief of Pain
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
JP4382735B2 (en) * 2005-10-06 2009-12-16 独立行政法人科学技術振興機構 Neuropathic pain treatment
ZA200809956B (en) * 2006-05-26 2010-07-28 Celgene Corp Methods and compositions using Immunomodulatory compounds in combination therapy
WO2008057196A2 (en) * 2006-10-19 2008-05-15 Celgene Corporation Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases
CN101696205B (en) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(substituted xylylenimine-2-yl)-2,6-dioxopiperidine polymorph and pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215114A (en) * 1976-11-12 1980-07-29 The Upjohn Company Analgesic N-[2-(furyl-methylamino and 2-thienylmethylamino)cycloaliphatic]be
DE69739802D1 (en) * 1996-07-24 2010-04-22 Celgene Corp Substituted 2- (2,6-dioxopiperidines-3-yl) -phthalimides -1-oxoisoindolines and methods for reducing TNF-alpha levels
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
SE0101256D0 (en) * 2001-04-06 2001-04-06 A & Science Invest Ab Treatment of low back pain

Also Published As

Publication number Publication date
AU2003286663B2 (en) 2009-08-13
BR0315609A (en) 2005-08-23
WO2004037199A3 (en) 2004-12-23
ZA200503240B (en) 2007-11-28
HK1088225A1 (en) 2006-11-03
CN1326522C (en) 2007-07-18
CN101108185A (en) 2008-01-23
NZ540028A (en) 2009-07-31
JP2006507284A (en) 2006-03-02
EP1556044A2 (en) 2005-07-27
WO2004037199A2 (en) 2004-05-06
AU2003286663A1 (en) 2004-05-13
CN1732000A (en) 2006-02-08
CA2503536A1 (en) 2004-05-06
KR20050057672A (en) 2005-06-16
MXPA05004182A (en) 2005-06-08

Similar Documents

Publication Publication Date Title
WO2005044178A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2005046318A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
HK1073427A1 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
MXPA05004778A (en) Methods of using and compositions comprising immunomudulatory compounds for the treatment and management of myeloproliferative diseases.
WO2005105088A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
WO2004037207A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
TW200626159A (en) Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor
IL178591A (en) 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for the treatment and management of myelodysplastic syndromes
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2004034962A3 (en) Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
WO2004041190A3 (en) Composition for the treatment of macular degenration
WO2005039497A3 (en) Methods and compositions comprising thalidomide for treatment of fibromyalgia
WO2005046594A3 (en) Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
NO20042758L (en) Procedure for treating a patient requiring analgesia.
WO2004029025A3 (en) Methods and compositions for the treatment of autoimmune disorders using clofarabine
GEP201606538B (en) Preoperative treatment of post operative pain
WO2004041181A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
WO2005065372A3 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
WO2005046592A3 (en) Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders
WO2004028463A3 (en) Methods and compositions for the treatment of lupus using clofarabine
IL164092A0 (en) The use of devazepide as analgesic agent